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Abstract  (word count:  49 words) 27 
False-positive galactomannan results have been reported, amongst others, in patients treated with 28 
gluconate containing solutions, such as Plasmalyte®.  GM optical density index was tested on 33 29 
distinct batches of Plasmalyte® and found to be negative in all, confirming that Plasmalyte® is no 30 
longer a cause of false-positive galactomannan results. 31 
 32 
Main text (word count: 1266) 33 
Invasive aspergillosis is a serious infection associated with a high mortality rate in patients at risk, 34 
such as patients receiving chemotherapy, patients undergoing allogeneic hematopoetic stem cell 35 
transplantation or patients admitted in the intensive care unit (ICU).  Galactomannan (GM), a fungal 36 
antigen produced by Aspergillus spp. during growth, is an important biomarker for early non-culture 37 
based diagnosis of invasive aspergillosis in immunocompromised patients.  Currently, positive serum 38 
testing on the GM enzyme immune-assay (Platelia Aspergillus, Bio-Rad, Marnes-La-Coquette, France) 39 
is one of the criteria for establishing the diagnosis of probable invasive aspergillosis in 40 
immunocompromised patients according to the European Organization for Research and Treatment 41 
of Cancer and Mycoses Study Group (EORTC/MSG) (1).  Since the last decade, GM testing is also 42 
applied on broncho-alveolar lavage (BAL) fluid, especially in non-neutropenic ICU patients, as this has 43 
been shown to have good sensitivity and specificity in diagnosing invasive aspergillosis in patients 44 
without the classic immunocompromising risk factors (2). 45 
 46 
An important limiting factor for GM testing is the association with false positive test results, which 47 
have been reported in patient serum or BAL fluid if the patient is treated with generic 48 
piperacillin/tazobactam and amoxicillin clavulanate (3,4). These antibiotics are produced by 49 
fermentation in Penicillium which generates GM recognized by the monoclonal antibody used in the 50 
Platelia® assay.   51 
 52 
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Plasmalyte®  (Baxter, Lessines, Belgium) is a sterile, nonpyrogenic electrolyte solution containing 53 
sodium chloride, potassium chloride, magnesium chloride, sodium acetate trihydrate, and 54 
bicarbonate ions with or without sodium gluconate.  It is used for fluid resuscitation and hydration in 55 
severely ill patients.    Fluid resuscitation in ICU patients has been a matter of debate during the last 56 
decade, with many studies investigating resuscitation efficacy in terms of hemodynamic and patient 57 
outcome vs. potential adverse effects, such as kidney injury and the need for renal replacement 58 
therapy (5).   Several studies suggested that balanced salt solutions, based on gluconate, acetate or 59 
lactate should be used preferentially in order to avoid side effects related to hyperchloremia and 60 
renal dysfunction associated with  normal saline, purely composed of chlorine salts (5).    Since 2012,  61 
Plasmalyte® , a balanced electrolyte solution, is  default resuscitation fluid in our hospital, particularly 62 
in septic critically ill patients,  as recommended in recent international consensus (6).    63 
 64 
In Belgium, only gluconate containing Plasmalyte®  solutions are available (Plasmalyte®  A Viaflo® and 65 
Plasmalyte®  148 + Glucose 5% Viaflo®, all containing 23 mEq/L gluconate).  Low molecular weight 66 
organic acids, such as gluconate, are produced by a fermentation process involving Aspergillus niger 67 
and Aspergillus terreus.  GM is released into the fermentation solution and is likely carried through 68 
the fractionation or filtration process for medical grade gluconate (7,8).  Although Plasmalyte® is 69 
sterile, GM still may persist in the gluconate containing solution, depending on the type and extent of 70 
fractionation and filtration, potentially resulting in false positive serum and BAL GM (7,8). 71 
 72 
When adding Plasmalyte® as preferred resuscitation fluid for ICU patients to our hospital’s drug 73 
formulary, a surveillance program was set up in order to follow-up GM index in every new batch of 74 
Plasmalyte®  circulating in our hospital. In short, 1 mL of Plasmalyte®  out of one bag of every new 75 
batch entering the hospital was tested using GM sandwich enzyme-linked immunosorbent assay 76 
according to the instructions of the manufacturer. Samples were considered positive if the GM 77 
optical density index (ODI) was ≥ 0.5.  Surprisingly, GM index was negative (< 0.1) in the first three 78 
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tested batches (13K 22T1A, 13I 24T1E and 13J 31T1E). Thirty additional batches, all circulating from 79 
January 2013 up to December 2014 in our hospital, were tested in order to confirm with 80% power 80 
that the probability for a false positive test is < 5% (based on a binomial test for a single proportion).   81 
GM index was negative (all < 0.1) in all 30 tested batches. 82 
These results are in contrast to what has been reported before in the literature.  Hage et al. were the 83 
first to report that Plasmalyte® is causing highly false-positive results (4.1-8.2) for GM in BAL fluid 84 
when using 100 mL Plasmalyte® as lavage fluid.9  The authors postulated that 1L of Plasmalyte®  85 
contained 10 µg of GM.  They assumed that if this would be administered intravenously to patients 86 
also serum GM would turn out to be false positive;  1 L of Plasmalyte®  would result in a serum GM 87 
concentration of 2.5 ng/mL assuming distribution in a plasma volume of 3 – 4 L (9).   Subsequently, 88 
this was indeed confirmed in a case report by Surmont and Stockman describing a patient treated 89 
with intravenous Plasmalyte® presenting with a false positive serum GM (1.85) which was ascribed to 90 
GM containing Plasmalyte®  (3.85) (10).  After discontinuation, GM tests became negative.  The 91 
authors confirmed false-positivity of serum GM by testing several patients treated with Plasmalyte®  92 
but without any sign of fungal infection (10).  In 2007,  Racil et al. reported a study in which healthy 93 
volunteers receiving Plasmalyte®  demonstrated false positive circulating GM persisting up to 24h 94 
(11).  This study confirmed again that, despite dilution in the intravascular compartment, GM levels 95 
are above the positivity threshold of the GM assay. Four different batches of Plasmalyte® were 96 
tested, all resulting in highly false positive GM values (7.15-8.53) (11). 97 
Petraitene et al. finally confirmed in 2011 that  sodium gluconate is the component in Plasmalyte®  98 
causing false-positive GM by comparing GM kinetics in rabbits treated with Plasmalyte® with and 99 
without gluconate (12).  100 
 101 
All above mentioned reports on false-positive GM linked to Plasmalyte®  dated from 2011 or before.  102 
Our tests, showing negative GM index on 33 batches, were undertaken between the end of 2012 and 103 
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up to 2015.  Baxter, the manufacturer of Plasmalyte®, confirmed that the number of providers of 104 
sodium gluconate delivering sodium gluconate to Baxter as one of the Plasmalyte® compounds was 105 
changed from two companies to a single provider in 2012 (personal communication Baxter Belgium 106 
& Europe, November 2015), potentially explaining the change from highly false positive GM to 107 
absence of GM in the batches produced after 2012.  A quick internet search reveals however that 108 
there are numerous providers of sodium gluconate worldwide, meaning that if the manufacturer 109 
would change the Plasmalyte®  production process  by working with an alternative provider in the 110 
future, absence of GM is no longer guaranteed.  Changes in the manufacturing process should 111 
however be managed in accordance with both current ICH guidelines and should be compliant to the 112 
Drug Product Marketing Authorisation. 113 
As the change in number of providers of sodium gluconate has only been adopted for Plasmalyte® 114 
distributed in the European Union, and as healthcare professionals are mostly not aware of changes 115 
in the manufacturing process,  the absence of false-positivity is restricted to the European Union and 116 
to the current manufacturing process.  Therefore, in our opinion,  GM testing should be incorporated 117 
as part of the quality control protocol at the level of the release of sodium gluconate by the provider, 118 
or at the reception of sodium gluconate by the company that is using this compound in 119 
manufacturing processes.  Ideally, absence of GM should be listed in the sodium gluconate 120 
monograph in the European or the United States Pharmacopeia, obliging providers in this way to 121 
optimize the filtration process and ultimately guaranteeing absence of GM false positivity at the 122 
bedside of the patient if drugs containing sodium gluconate are prescribed. 123 
 124 
In conclusion, it seems that Plasmalyte®  can actually be used in a safe way as resuscitation fluid in 125 
critically ill patients, without generating false positive serum or BAL GM values.  It is important that 126 
manufacturers of electrolyte solutions containing gluconate pursue methods to control for absence 127 
of GM, as false positive GM has the potential to lead to useless antifungal treatment that can result 128 
in potential adverse events and additional costs. 129 
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